|
|
Article: MDS Nordion Launches Theryttrex in Europe.
- Article from:
- PR Newswire
- Article date:
- April 22, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
ROSTOK, Germany, April 22 /PRNewswire/ --
- Radiopharmaceutical-grade yttrium-90 used in production of first radioimmunotherapeutic product approved for use in EU
ROSTOK, Germany, April 22 /PRNewswire/ --
MDS Nordion today announced the launch of Theryttrexa, MDS Nordion's radiopharmaceutical grade yttrium-90 (Y-90), at the German Congress of Nuclear Medicine held in Rostok, Germany. Theryttrex is used as a precursor to radiolabel Zevalin(R)(1), the first radioimmunotherapeutic product approved in the EU for the treatment of non- Hodgkin's Lymphoma. Radioimmunotherapeutics are manufactured by labelling, or linking, radioactive isotopes to ...